Kornimate/medical-research-clean huggingface dataset:
basic hematological parameters and coagulation profile in type 1 diabetic children

Conditions: Type 1 Diabetes Mellitus

Summary: diabetes mellitus is a group of chronic metabolic diseases characterized by hyperglycemia .type 1 diabetes is a heterogeneous disease related to the destruction of pancreatic beta cells and is a result of absolute lack of insulin * diabetes mellitus has been traditionally looked upon as a disease of adults (except type i diabetes), however it can affect individuals of any age. given the peculiarities and problems that it carries, diabetes in children and adolescents poses special challenges to the entire society. diabetes is the second commonest chronic disease occurring in 1 in every 1500 children by age 5 and in 1 in 350 children by age 8 . microvascular (retinopathy, neuropathy, and nephropathy) aim of the research to assess basic hematological parameters and coagulation profiles among type 1 diabetic children and compare them with healthy controls and macrovascular (coronary artery disease, peripheral vascular disease, and cerebrovascular disease) atherothrombotic complications may occur in children and adolescents, depending on the duration of diabetes, the degree of metabolic control, and other factorssuch as genetics . diabetes mellitus can cause blood disorders such as deformity of red blood cells and increase their adhesion \[6\].it has an effect on the function of red blood cells through the interaction with the membrane and intracellular components . red blood cell distribution width (rdw) is a measure of the difference in the size of red blood cells. an increase in rdw can be caused by anemia or nutritional deficiencies related to anemia * studies have shown that the average number of red blood cells, hemoglobin and hematocrit in diabetic patients is lower than the control group, which indicates the presence of anemia in diabetic patients .


Eligibility criteria:
inclusion criteria: * age from one month to 18 year. * both sexes. * patients known to have type 1 diabetes. exclusion criteria: * patients less than one month and more than 18years. * history of bleeding disorders or anemia unrelated to diabetes. * otherc types of diabetes .
precision diagnosis and therapy for early stage lung cancer

Conditions: Lung Cancer

Summary: the present study is a single arm clinical trial aiming to improve the key technology in the diagnosis and treatment of early stage lung cancer. 60,000 high-risk subjects (age 45-70) are planned to recruit and assign to the low dose computed tomography (ldct) screening arm (baseline + 2 rounds of biennial repeated ldct screening). management of positive screening test will be carried out by a pre-specified protocol.


Eligibility criteria:
inclusion criteria: • eligible participants were those aged 45-70 years, and with either of the following risk factors: 1. history of cigarette smoking ≥ 20 pack-years, and, if former smokers, had quit within the previous 15 years; 2. malignant tumors history in immediate family members; 3. personal cancer history; 4. professional exposure to carcinogens; 5. long term exposure to second-hand smoke; 6. long term exposure to cooking oil fumes. exclusion criteria: 1. had a ct scan of chest within last 12 months 2. history of any cancer within 5 years

Keywords: early stage lung cancer ldct screening lung resection electromagnetic navigation bronchoscopy peripheral biomarker
myo-electrical and nerve root function response to focused extracorpeal shock wave in cervical radiculopathy

Conditions: Cervical Radiculopathy

Summary: background: upper limb nerve root dysfunction with increased active myofascial trigger point in upper trapezius is common problem in patients with cervical radiculopathy. the purpose of this study was to evaluate the effect of extracorpeal shock wave on the myo-electric and nerve function responses in patients with cervical radiculopathy.

randomized controlled clinical trial among forty eight (48) patients with cervical radiculopathy. they will be allocated randomly by sealed envelopes into two groups: group (a): will receive a designed physical therapy program in addition to sham extracorpeal shock wave on upper trapezius. group (b): will receive focused extracorpeal shock wave on the active myofascial trigger points in upper trapezius in addition to the same physical therapy program as in group a. somatosensory evoked potential for upper limb median nerve will be applied using the electromyography (emg) device. hand grip strength will be assessed using the handheld dynamometer (hhd) , level of radiating pain will be assessed using the numeric rating scale , pain and tenderness in upper trapezius muscle will be also assessed using pressure pain threshold (ppt).

Eligibility criteria:
inclusion criteria: 1. all patients suffer from unilateral discogenic cervical radiculopathy of lower cervical spine(c5-c6 and/ or c6-c7) as confirmed with mri. 2. all patients suffer from pain and tenderness on active trigger points of the upper trapezius . 3. age ranging from 36 to 46 years old. 4. duration of symptoms more than 3 months to avoid acute stage of inflammation. 5. side to side amplitude differences of 50% or more in dsseps measurement (naguszewski et al.,2001) exclusion criteria: 1. posterior osteophytes 2. spinal canal stenosis 3. rheumatoid arthritis 4. vestibular insufficiency 5. osteoporosis 6. any signs or symptoms of myelopathy 7. any abnormalities of deep sensation 8. associated pathologies of upper cervical region or the upper limb that may cause overlapping with clinical findings as referred pain from costotransverse joint, rotator cuff tendonitis, cervical rib syndrome and entrapment neuropathy.

Keywords: cervical radiculopathy nerve root dysfunction trigger points focused extracorpeal shock wave
effectiveness of tranexamic acıd application wıth different doses on bleeding, edema and physician comfort in orthognathıc surgery patients

Conditions: Tranexamic Acid; Orthognathic Surgery; Edema; Bleeding

Summary: the aim of this clinical study conducted in accordance with the information in the literature is to compare the effects of administering tranexamic acid during orthognathic surgery, at different doses. specifically, investigators aim to compare the effects of administering 1 ampoule iv (approximately 3 mg/kg) and 2 ampoules iv (approximately 6 mg/kg), and evaluate their impact on intraoperative bleeding (ml), surgical duration (min), postoperative swelling, and intraoperative surgical field evaluation (fromme scale), by comparing them with control group (applying no drug administration) patient data.

this prospective double blind clinical study was approved by the bezmialem vakif university clinical research ethics committee (2022-e.6706). all patients were provided detailed explanations of the surgical procedure and potential adverse events, underwent preoperative anesthesia assessments, and provided informed consent. a total of 60 patients were included in the study and were randomly assigned to three groups: study group 1 (n=20), study group 2 (n=20), and control group (n=20). in study group 1, patients received local anesthesia prior to bimaxillary osteotomy, followed by intravenous administration of 250 mg / 2.5 ml tranexamic acid before starting with the incision. in study group 2, patients also received local anesthesia before bimaxillary osteotomy, followed by intravenous administration of 250 mg / 2.5 ml tranexamic acid for le fort 1 and, a second dose of 250 mg / 2.5 ml tranexamic acid was administered for beginning of the sagittal split osteotomy. the control group, group 3, did not receive any medication before or after surgery. all patients underwent bimaxillary surgery using the same surgical technique and same surgical team.

Eligibility criteria:
inclusion criteria: 1. patients with class 2 or class 3 dentofacial malformation who are planned to undergo bimaxillary orthognathic surgery. 2. patients who have not had orthognathic surgery before 3. patients without cleft lip and palate 4. patients without systemic bleeding diets exclusion criteria: 1. having a systemic disease that affects general health status 2. presence of a malignant disease in the head and neck region 3. patients who have previously undergone orthognathic surgery 4. patients with any bleeding disorders
multiple sclerosis and extract of cannabis (musec) study

Conditions: Muscle Spasticity

Summary: study objectives: to determine the efficacy and safety of a standardised extract of cannabis sativa given orally 2 times daily as compared to placebo for the relief of muscle stiffness and pain in multiple sclerosis for a period of 12 weeks. study patients: 400 patients with multiple sclerosis (age 18-64, stable disease during previous 6 months, ambulatory or not, antispasticity medication and physiotherapy stabilised ≥ 30 days) with experiencing muscle stiffness ≥ 4 on a 11-point numerical likert scale at baseline. study treatment: group 1: cannabis extract (delta-9-thc 2.5mg, cbd 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg thc/d, administered twice daily, additionally to previous antispasticity and analgesic medication. group 2: matched placebo, twice daily, additionally to previous antispasticity and analgesic medication. treatment schedule: start dose 5 mg thc/d, individual dose titration with increase of 5 mg thc every 3 days, maximal total daily dose 25 mg thc, administered as 2 equal doses based on tolerability. treatment duration: 12 weeks. study sites: 20 neurological clinics in the united kingdom.


Eligibility criteria:
inclusion criteria: * signed informed consent. * diagnosis of ms according to mcdonald criteria. * current muscle stiffness ≥ 4 on a 11-point categorical rating scale. * on-going troublesome muscle stiffness for at least 3 months. * stable disease for the previous 6 months. * antispasticity medication and physiotherapy stabilised for the last 30 days. * patients may be ambulatory or not. * age 18-64. exclusion criteria: * immunosuppressants which may affect spasticity (including corticosteroids and interferon but ex-cluding azathioprine) taken currently or in previous 30 days * past or present history of psychotic illness. * open/infected pressure sores or other source of chronic infection. * significant fixed tendon contractures. * severe cognitive impairment such that the patient is unable to provide informed consent. * history of clinically important renal, cardiovascular or neurol. diseases (apart from ms). * malignancy within the past 2 years. * cannabinoids taken currently or in previous 30 days. * positive qualitative urinary test on cannabinoids at screening visit. (in this case a patient will be allowed to repeat the test at a second screening visit later.) * known hypersensitivity to cannabinoids. * current drug abuse, including alcohol abuse. * laboratory parameters outside the following limits: creatinine \> 3x upper limit of normal bilirubine \> 3x upper limit of normal transaminases \> 5 x upper limit of normal * anticipated immunisations within the 12 weeks of trial participation. * other problems likely to make participation difficult at the discretion of the neurologist. * women who are pregnant, lactating or not using adequate contraception. * participation in other treatment studies currently or within the previous month.

Keywords: multiple sclerosis muscle stiffness spasticity pain treatment cannabinoids
start-j: sitagliptin in elderly trial in japan

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to compare the efficacy and the safety of sitagliptin and glimepiride in drug naïve elderly patients with type 2 diabetes as evaluated by hba1c change from baseline at 52 w as efficacy and incidence of hypoglycemia from randomization to 52 w as safety. the clinical hypotheses are non-inferiority of sitagliptin to glimepiride in efficacy as judged by hba1c change from baseline at 52 w and superiority of sitagliptin to glimepiride in safety as judged by incidence of hypoglycemia in drug naïve elderly patients with t2dm. in addition, comparison of efficacy is extended to 104 w.


Eligibility criteria:
inclusion criteria: 1. patients with type 2 diabetes who are oral hypoglycemic agent naive or, α-glucosidase inhibitor or biguanide monotherapy (to be washed out 4 weeks prior to randomization) 2. signed informed consent obtained before any trial-related activities 3. treatment with diet and exercise for 12 weeks and longer at screening 4. age =\>60 y.o. 5. male and female 6. hba1c 6.9%=\< \<8.9% exclusion criteria: 1. active proliferative retinopathy or maculopathy requiring treatment 2. liver dysfunction (\>x2 of upper normal limit), moderate or severe renal dysfunction(serum cr\>1.5mg/dl in male, cr\>1.3mg/dl in female, egfr\<30), severe cardiac disease (nyha iii or iv), malignancy or uncontrolled hypertension (treated or untreated) as judged by the investigator 3. mental incapacity (including moderate or severe dementia) precluding adequate understanding and/or cooperation as judged by the investigator 4. recurrent hypoglycaemia or hypoglycaemic unawareness as judged by the investigator 5. previous history of severe allergy to pharmaceutical products 6. systemic glucocorticoids users or potential users 7. suspected type 1 diabetes (including slowly progressive insulin dependent diabetes mellitus) or positive anti-glutamic acid decarboxylase antibody 8. any condition that the investigator considers a potential obstacle to trial participation and/or data analysis

Keywords: type 2 diabetes sitagliptin glimepiride elderly patients japanese
peng vs ficb for hip fracture in ed patients

Conditions: Femoral Neck Fractures; Intertrochanteric Fractures

Summary: regional anesthesia for hip fractures has been shown to decrease rates of delirium in elderly patients with hip fractures as well as improve pain compared to systemic opioids. the pericapsular nerve group (peng) block has recently received attention as an alternative approach to femoral nerve block and fascia iliaca compartment block (ficb). the investigators seek to evaluate if there is a difference between the peng and ficb in terms of efficacy of pain control in ed patients presenting with hip fracture. we hypothesize that the peng block may be superior based on previous research.

fractures of the proximal femur are a common presentation to the emergency department and are an acutely painful condition. this condition predominantly affects elderly patients who are at risk for delirium and more susceptible to the adverse effects of systemic opioids. regional anesthesia is an recommended component of pain control for elderly patients with hip fracture. the investigators seek to compare the efficacy of pain control of the pericapsular nerve group (peng) block with the fascia iliaca compartment block (ficb). previous studies have suggested that the peng block may be superior to the ficb for pain control and results in less thigh motor weakness. the investigators will compare pain control (by difference in mean vas score at set time points), systemic opioid use (in mean morphine equivalents prior to surgery), and motor function in patients with hip fractures who receive either block in the ed.

Eligibility criteria:
inclusion criteria: * proximal femur fracture exclusion criteria: * refusal to consent * hemodynamic instability * allergy to local anesthetics * severe injury with instability * severe medical conditions with instability

Keywords: peng ficb fascia iliaca compartment block pericapsular nerve group block hip fracture
comparison of an isotonic balanced fluid, sterofundin® , with 0.9% saline in traumatic brain injury(tbi)

Conditions: Brain Injuries

Summary: the main objective of this study is to compare the clinical outcomes of tbi patients receiving only sterofundin or 0.9% saline as main fluid therapy.

study design: prospective single centre double-blind randomized controlled trial study endpoints/outcomes primary outcomes: * 30 day mortality * functional neurological outcomes at 6 months based on extended glasgow outcome scale (gos-e) secondary outcomes: * acid-base and electrolyte balance * daily mean change in intracranial pressure (icp) * episodes of intracranial hypertension * duration of mechanical ventilation * length of icu stay and icu mortality study duration: 2 years site: ummc. departments involved: emergency medicine, surgery, anaesthesiology and pharmacy methodology. investigators will assess patients admitted to the emergency department, ummc, for eligibility. randomisation: investigators will randomize patients in a 1:1 ratio to either 0.9% saline intravenous fluid group or sterofundin® intravenous fluid group. an independent statistician not involved with the research will perform a block of eight randomisation using computerised number generator list. conduct of study the department of pharmacy will identically seal all 0.9% saline and sterofundin® intravenous fluid bottles and label them, according to their type, as either a or b. the patients, investigators and medical and nursing staff will not be aware of the designation of the letters a and b to the fluids. investigators will administer the study fluid will immediately after patient randomisation and this will last for 72 hours. other general care of the traumatic brain injury patients from both study arms will continue as per neurosurgical unit protocol and brain trauma foundation guidelines. data handling investigators will collect all data relevant to both primary and secondary outcomes (see also attached proforma): statistical analysis investigators will conduct students t test, chi squared and the mann-whitney u test as appropriate. investigators will adjust results with univariable and multivariable logistic regression and report their odds ratio. investigators will present survival analysis using kaplan meier curves and compare them using log rank test.

Eligibility criteria:
inclusion criteria: * patients age between 18 and 65 years of age * non-penetrating moderate (gcs 9-12) or severe (gcs 3-8) traumatic brain injury * within 12 hours since the recorded time of injury exclusion criteria: * pregnancy * polytrauma * cardiac arrest at presentation * gcs of three with bilateral fixed dilated pupils, * evidence of severe cardiac, respiratory, renal or liver dysfunction

Keywords: traumatic brain injury isotonic balanced fluid
effect of modified constraint-induced movement therapy combined with virtual reality on mobility in post-stroke patients: a randomized control trial

Conditions: Post Stroke; Mobility; Balance

Summary: this study investigates the effectiveness of combining m-cimt and vr to improve mobility in post-stroke patients. a non-blinded randomized controlled trial will be conducted with 32 participants divided equally into experimental and control groups using purposive sampling. the experimental group will receive m-cimt with vr training, while the control group will receive m-cimt with task-specific functional training. sessions will be 30 minutes per day, 4 days a week, for 6 weeks. outcomes will be measured using fma-le, bbs, dgi, tug, and ss-qol. the study will take place over one year at ffh and fucp, with ethical approval from erc fumc.


Eligibility criteria:
inclusion criteria: * sample selection criteria inclusion criteria * sub-acute and chronic stroke patient \>3months * males and females of 40-60 years. * mini-mental state examination score ≥24 * fac scale = 3 * limited spasticity (0,1,1⁺) according to modified ashworth scale * adequate balance and walking ability while wearing the constraint to be eligible to participate in cimt intervention. exclusion criteria * patient with severe spasticity and pain * patient of epilepsy, parkinson's disease and stage 4 arthritis * patient with global aphasia * individuals suffering from unstable angina, symptomatic heart failure, or uncontrolled hypertension * patients with any traumatic musculoskeletal injury and surgery of lower limb

Keywords: stroke rehabilitation hemiplegia therapy motor activity gait physiology neuroplasticity movement disorders rehabilitation constraint-induced movement therapy virtual reality therapy lower extremity pathophysiology
ivabradine for rate control in permanent atrial fibrillation

Conditions: Atrial Fibrillation; Atrial Fibrillation, Persistent

Summary: ivabradine may be useful as a rate controlling agent in atrial fibrillation without negative effects on hemodynamics and inotropy. the objective in this proof of concept study is to investigate the hypothesis that ivabradine will slow the ventricular response in patients with permanent atrial fibrillation and previously-implanted pacemakers.

in a simple cross-over study, the investigators will evaluate the impact of oral ivabradine on exercise treadmill test, percent pacing as stored in pacemaker diagnostics, and 6 minute walk test. aim/hypotheses • to determine if the addition of ivabradine to baseline cardiac medications slows mean and maximum heart rates in permanent atrial fibrillation * ivabradine will lower mean and maximum heart rates on treadmill exercise test, without lowering blood pressure * ivabradine will increase percent pacing, and lower rates over time as shown on pacemaker diagnostic data * ivabradine will improve exertional symptoms and exercise tolerance due to atrial fibrillation as measured by the borg's scale during a six-minute walk test. study design 1. patients with permanent atrial fibrillation will undergo baseline exercise treadmill test, measurement of heart rates and percent pacing from pacemaker diagnostics, and a 6 minute walk test with symptomatic assessment of dyspnea using the borg's scale score. 2. oral ivabradine will be started at 5 mg twice daily, and up-titrated to a maximum dose of 7.5 mg twice daily at 7 days if percent pacing has not increased significantly or rates have not slowed more than 20bpm. 3. exercise treadmill test, measurement of heart rates and percent pacing from pacemaker diagnostics, and a 6 minute walk test with symptomatic assessment of dyspnea using the borg's scale score will be repeated at 2 weeks.

Eligibility criteria:
inclusion criteria: * patients with stable blood pressures with permanent atrial fibrillation and implanted pacemaker pacing less than 50% of the time, with or without concomitant beta blocker or calcium channel blocker use exclusion criteria: * patients with uncontrolled hypertension will be excluded * to eliminate confounding effects, patients on digoxin therapy will be excluded * patients on anti-arrhythmic therapy * patients with pre-excitation on ekg * patients who pace \> 50% of the time * patients with severe child-pugh c hepatic impairment